Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions

Cattani, Paola; Cerimele, Francesca; Porta, Daniela; Graffeo, Rosalia; Ranno, Stefania; Marchetti, Simona; Ricci, Riccardo; Capodicasa, Natale; Fuga, L.; Amico, Rivet; Cherchi, Gian Mario; Gazzilli, M.; Zanetti, Stefania Anna Lucia; Fadda, Giovanni

doi:10.1046/j.1469-0691.2003.00490.x

Cited by 80 publications

(53 citation statements)

References 31 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results also revealed an excess for persons born in two adjacent provinces in the northern region of Lombardy, which is consistent with the increased incidence of CKS and high HHV8 seroprevalence in another adjacent province (Ascoli et al, 2001;Tanzi et al, 2005). These provinces are located in the Po Valley, which, together with Sardinia, Sicily, and Puglia, has shown evidence of a higher incidence of CKS and seroprevalence of HHV8, compared with other areas in Italy (Lospalluti et al, 1995;Calabro et al, 1998;Whitby et al, 2000;Cattani et al, 2003). This could be related to environmental risks, including having been born in areas with endemic malaria (Geddes et al, 1995) and exposure to bloodsucking insects (Coluzzi et al, 2002;Ascoli et al, 2006).…”

Section: Discussionsupporting

confidence: 60%

“…Given that the area of birth is an important determinant because HHV8 is mostly acquired during childhood (Whitby et al, 2000;Cattani et al, 2003), we also calculated the SMRs for the region of birth (not recorded on the multiple-causes-of-death records), by linking the multiple-causes-of-death records with the National Mortality Database, using the individual anonymous six-digit identification code adopted for both databases. However, as the region of birth has been recorded in the National Mortality Database only since 1998, this linkage was only possible for 679 persons.…”

Section: Geographical Distribution Of Deceased Persons With Cksmentioning

confidence: 99%

See 1 more Smart Citation

Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995–2002)

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Little information is available on the causes of death among persons with classic Kaposi's sarcoma (CKS). METHODS: We conducted a population-based study in Italy to identify deceased persons with CKS and the underlying causes of death among them, by reviewing multiple-causes-of-death records. Standardised mortality ratios (SMRs) and 95% confidence intervals were calculated to compare the distribution of causes to that among the same-age general population of deceased persons. The geographical distribution was also evaluated. RESULTS: Of the 946 deaths among persons with CKS, 65.9% were attributable to non-neoplastic conditions and 21.9% to malignancies. For 12.2%, no lethal pathology was identified and CKS was considered as the underlying cause. In 90% of these cases, there was visceral/nodal involvement, therapy-related complications, or neoplastic cachexia. Among persons with CKS who died of other causes, an excess for lymphoid malignancies emerged (SMR ¼ 4.40) (chronic lymphocytic leukaemia (11.03), non-Hodgkin's lymphoma (4.22), Hodgkin's lymphoma (11.80), and multiple myeloma (2.3)), balanced by a deficit for all solid cancers (0.56), with a marked deficit for lung cancer (0.41). We found an excess for respiratory diseases (chronic obstructive pulmonary disease (1.86)) and genitourinary diseases (chronic renal failure (6.47)). There was marked geographical heterogeneity in the distribution of deaths. CONCLUSIONS: Though referring specifically to Italy, the results are informative for other countries and populations and all cases of CKS in general.

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Geographical Distribution Of Deceased Persons With Cksmentioning

confidence: 99%

Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995–2002)

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The application of different serologic assays makes it difficult to compare directly the prevalence of HHV-8 antibodies in different populations [Rabkin et al, 1998]. Still, this study suggests that HHV-8 is prevalent in Greece, in the range observed in other Mediterranean countries [Calabro et al, 1998;Iscovich et al, 2000;Perna et al, 2000;Gambus et al, 2001;Cattani et al, 2003]. In particular, HHV-8 seroprevalence in the J. Med.…”

Section: Discussionmentioning

confidence: 86%

“…Virol. DOI 10.1002/jmv general population from Western Sicily is reported to be 11.5% , whereas the corresponding estimate for healthy individuals from Sardinia, Central-Southern Italy, and Albania is reported to be higher (25.0%, 18.3%, and 20.0%, respectively) [Cattani et al, 2003;Schinaia et al, 2004]. The prevalence of HHV-8 antibodies observed in the current study is in accordance with the seroprevalence rates reported in healthy adults from Israel (6.1%, 95% CI: 2.0, 10.1) [Iscovich et al, 2000] and in Spanish blood donors (6.5%, 95% CI: 4.6, 8.5) [Gambus et al, 2001].…”

Section: Discussionmentioning

confidence: 93%

Human herpesvirus 8 (HHV‐8) infection in healthy urban employees from Greece: Seroprevalence and associated factors

Sypsa¹,

Petrodaskalaki²,

Kalapothaki³

et al. 2007

Journal of Medical Virology

View full text Add to dashboard Cite

A cross-sectional study was carried out in healthy company employees from Greece with the aim of assessing the prevalence of human herpesvirus 8 (HHV-8) and identifying risk factors for this herpesviral infection. Serum samples obtained from 955 subjects were tested for antibodies to HHV-8 by the K8.1 enzyme-linked immunosorbent assay (ELISA). Associations between HHV-8 serostatus and potential risk factors were examined using t-test, chi square test, and multivariate logistic regression analysis. HHV-8 prevalence was 7.6% (95% confidence interval (CI): 6.0%, 9.5%) and it increased with age from 6.5% among <30 years old to 13.8% among > or =50 years old subjects (P = 0.006). HHV-8 seropositivity was independently associated with endoscopic examination (odds ratio (OR): 2.01; 95% CI: 1.09, 3.70; P = 0.026), HBsAg positivity (OR: 5.16; 95% CI: 2.02, 13.20; P = 0.001) and age (OR > or =50 years old vs. <50 years old: 2.09; 95% CI: 1.23, 3.52; P = 0.006). No statistically significant associations between HHV-8 positive status and gender, occupational status, surgery, transfusion, tattoos/body piercing, multiple sex partners, weakness/fatigue, HCV status were observed. HHV-8 is prevalent in Greece. The strong association between HBV infection and HHV-8 positive status supports the hypothesis of an association between these two viral infections. The association between HHV-8 seropositivity and endoscopic examination requires further investigation.

show abstract

“…Approximately 95% of KS lesions show polymerase chain reaction (PCR) evidence of HHV8 infection [1]. KS is classically seen as a complication of HIV infection and in older men of Mediterranean, Central and Eastern European heritage [2]. However, iatrogenic KS can also occur in patients undergoing immunosuppressive therapies for autoimmune disorders and in patients who are transplant recipients [1].…”

Section: Letter To the Editormentioning

confidence: 99%

A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura

et al. 2016

View full text Add to dashboard Cite

show abstract

Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions

Cited by 80 publications

References 31 publications

Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995–2002)

Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995–2002)

Human herpesvirus 8 (HHV‐8) infection in healthy urban employees from Greece: Seroprevalence and associated factors

A case report of iatrogenic cutaneous Kaposi sarcoma due to rituximab therapy for thrombotic thrombocytopenic purpura

Contact Info

Product

Resources

About